Prospective evaluation of a facilitated referral pathway to improve uptake of genetic assessment for women with newly diagnosed ovarian cancer.

Approximately 30% of ovarian cancer is attributable to germline mutations and genetic assessment is recommended for all women with ovarian cancer. However, only 15-30% of women are currently being offered genetic evaluation. We sought to determine if a patient-centered, facilitated genetics referral pathway whereby all newly diagnosed ovarian cancer patients are immediately contacted by a genetics navigator to schedule genetic assessment as part of routine care could increase rates of genetic counseling and uptake of genetic testing.